Correlation among 16 biological factors [p53, p21waf1, MIB-1 (Ki-67), p16INK4A, cyclin D1, E-cadherin, Bcl-2, TNF-α, NF-κB, TGF-β, MMP-7, COX-2, EGFR, HER2/neu, ER, and HIF-1α] and clinical outcomes following curative chemoradiation therapy in 10 patients with esophageal squamous cell carcinoma

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 903-910

  Shibata Kobayashi, Shino ^a   Yamashita, Hideomi ^a   Okuma, Kae ^a   Shiraishi, Kenshiro ^a   Igaki, Hiroshi ^a   Ohtomo, Kuni ^a   Nakagawa, Keiichi ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Biological markers; Esophageal cancer; Imunohistochemistry; Prognostic factors; Squamous cell carcinoma

Indexed keywords

BIOLOGICAL FACTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; MATRILYSIN; NEDAPLATIN; PROTEIN BCL 2; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRRADIATION; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84872713094     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1130     Document Type: Article

References (36)

1. Sarbia M, Stahl M, Fink U, Willers R, Seeber S and GabbertHE: Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 4: 2991-2997, 1998.
2. Takeuchi H, Ozawa S, Ando N, Kitagawa Y, Ueda M and Kitajima M: Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol 10: 792-800, 2003.
3. Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, Nakajima K, Nishida T, Mori M and Doki Y: p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol 17: 804-811, 2010.
4. Ishida M, Morita M, Saeki H, Ohga T, Sadanaga N, Watanabe M, Kakeji Y and Maehara Y: Expression of p53 and p21 and the clinical response for hyperthermochemoradiotherapy in patients with squamous cell carcinoma of the esophagus. Anticancer Res 27: 3501-3506, 2007.
5. Ressiot E, Dahan L, Liprandi A, Giorgi R, Djourno XB, Padovani L, Alibert S, Ries P, Laquière A, Laugier R, Thomas P and Seitz JF: Predictive factors of the response to chemoradiotherapy in esophageal cancer. Gastroenterol Clin Biol 32: 567-577, 2008.
6. Malik SM, Nevin DT, Cohen S, Hunt JL and Palazzo JP: Assessment of immunohistochemistry for p16INK4 and high-risk HPV DNA by in situ hybridization in esophageal squamous cell carcinoma. Int J Surg Pathol 19: 31-34, 2011.
7. Sarbia M, Stahl M, Fink U, Heep H, Dutkowski P, Willers R, Seeber S and Gabbert HE: Prognostic significance of cyklin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer 84: 86-91, 1999.
8. No authors listed: Prognostic significance of CyclinD1 and E-Cadherin in patients with esophageal squamous cell carcinoma: multiinstitutional retrospective analysis. Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Diseases. J Am Coll Surg 192: 708-718, 2001.
9. Kuwahara A, Yamamori M, Fujita M, Okuno T, Tamura T, Kadoyama K, Okamura N, Nakamura T and Sakaeda T: TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res 29: 100, 2010.
10. Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB and Ajani JA: Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 5: 2844-2850, 2006.
11. Pühringer-Oppermann F, Sarbia M, Ott N and Brücher BL: The predictive value of genes of the TGF-beta1 pathway in multimodally treated squamous cell carcinoma of the esophagus. Int J Colorectal Dis 25: 515-521, 2010.
12. Yamashita K, Mori M, Shiraishi T, Shibuta K and Sugimachi K: Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 6: 1169-1174, 2000.
13. Takatori H, Natsugoe S, Okomura H, Matsumoto M, Ishigami S, Owaki T and Aikou T: Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma. Oncol Rep 13: 697-701, 2005.
14. Akutsu Y, Hanari N, Yusup G, Komatsu-Akimoto A, Ikeda N, Mori M, Yoneyama Y, Endo S, Miyazawa Y and Matsubara H: COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 18: 2946-2951, 2011.
15. Gotoh M, Takiuchi H, Kawabe S, Ohta S, Kii T, Kuwakado S and Katsu K: Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn J Clin Oncol 37: 652-657, 2007.
16. Ogawa K, Chiba I, Morioka T, Shimoji H, Tamaki W, Takamatsu R, Nishimaki T, Yoshimi N and Murayama S: Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy. Anticancer Res 31: 2351-2359, 2011.
17. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, HallerDG and Morrow M: AJCC Cancer Staging Handbook. 5th edition. Lippincott-Raven, Philadelphia, PA, 1997.
18. Yamashita H, Okuma K, Wakui R, Kobayashi-Shibata S, Ohtomo K and Nakagawa K: Details of recurrence sites after elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) combined with chemotherapy for thoracic esophageal squamous cell carcinoma-a retrospective analysis. Radiother Oncol 98: 255-260, 2011.
19. Yamashita H, Okuma K, Seto Y, Mori K, Kobayashi S, Wakui R, Ohtomo K and Nakagawa K: A retrospective comparison of clinical outcomes and quality of life measures between definitive chemoradiation alone and radical surgery for clinical stage II-III esophageal carcinoma. J Surg Oncol 100: 435-441, 2009.
20. Yamashita H, Nakagawa K, Yamada K, Kaminishi M, Mafune K and Ohtomo K: A single institutional non-randomized retrospective comparison between definitive chemoradiotherapy and radical surgery in 82 Japanese patients with resectable esophageal squamous cell carcinoma. Dis Esophagus 21: 430-436, 2008.
21. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC: Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576, 1996.
22. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
23. Yerushalmi R, Woods R, Ravdin PM, Hayes MM and GelmonKA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183, 2010.
24. Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A and Zamora A: The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol) 19: 154-61, 2007.
25. Koltz BR, Hicks DG and Whitney-Miller CL: HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options. Biotech Histochem 87: 40-45, 2012.
26. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, Tsurumaru M and Sasai K: c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 57: 1323-1327, 2003.
27. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A and Fujii H: Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 92: 1253-1260, 2005.
28. Wang QM, Yuan L, Qi YJ, Ma ZY and Wang LD: Estrogen analogues: promising target for prevention and treatment of esophageal squamous cell carcinoma in high risk areas. Med Sci Monit 16: HY19-HY22, 2010.
29. Lane DP: A death in the life of p53. Nature 362: 786-787, 1993.
30. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 Is a universal inhibitor of cyclin kinase. Nature 366: 701-704, 1993.
31. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, CanmanCE, Jackman J, Pietenpol JA, Burrell M, Hill DE and Wang Y: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
32. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
33. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
34. Legan M: Cyclooxygenase-2, p53 and glucose transporter-1 as predictors of malignancy in the development of gallbladder carcinomas. Bosn J Basic Med Sci 10: 192-196, 2010.
35. Ii M, Yamamoto H, Adachi Y, Maruyama Y and Shinomura Y: Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 231: 20-27, 2006.
36. Smith TG, Robbins PA and Ratcliffe PJ: The human side of hypoxia-inducible factor. Br J Haematol 141: 325-334, 2008.